BNP Paribas Financial Markets’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-171,397
| Closed | -$273K | – | 3505 |
|
|
2024
Q1 | $273K | Sell |
171,397
-49,259
| -22% | -$78.3K | ﹤0.01% | 2486 |
|
|
2023
Q4 | $190K | Buy |
220,656
+133,999
| +155% | +$115K | ﹤0.01% | 2536 |
|
|
2023
Q3 | $92.7K | Buy |
86,657
+46,350
| +115% | +$49.6K | ﹤0.01% | 2673 |
|
|
2023
Q2 | $104K | Sell |
40,307
-1,516
| -4% | -$3.93K | ﹤0.01% | 2626 |
|
|
2023
Q1 | $171K | Buy |
41,823
+13,808
| +49% | +$56.3K | ﹤0.01% | 2574 |
|
|
2022
Q4 | $141K | Buy |
28,015
+10,923
| +64% | +$54.8K | ﹤0.01% | 2480 |
|
|
2022
Q3 | $224K | Buy |
17,092
+2,014
| +13% | +$26.3K | ﹤0.01% | 2747 |
|
|
2022
Q2 | $193K | Sell |
15,078
-6,934
| -32% | -$88.9K | ﹤0.01% | 2477 |
|
|
2022
Q1 | $336K | Sell |
22,012
-4,781
| -18% | -$72.9K | ﹤0.01% | 2389 |
|
|
2021
Q4 | $475K | Buy |
26,793
+19,124
| +249% | +$339K | ﹤0.01% | 2416 |
|
|
2021
Q3 | $161K | Buy |
7,669
+4,354
| +131% | +$91.5K | ﹤0.01% | 2537 |
|
|
2021
Q2 | $65.4K | Sell |
3,315
-119
| -3% | -$2.35K | ﹤0.01% | 2580 |
|
|
2021
Q1 | $99.8K | Sell |
3,434
-1,123
| -25% | -$32.6K | ﹤0.01% | 2795 |
|
|
2020
Q4 | $138K | Sell |
4,557
-1,709
| -27% | -$51.8K | ﹤0.01% | 2420 |
|
|
2020
Q3 | $99.7K | Buy |
6,266
+5,138
| +455% | +$81.7K | ﹤0.01% | 2505 |
|
|
2020
Q2 | $22.3K | Sell |
1,128
-6,412
| -85% | -$127K | ﹤0.01% | 2724 |
|
|
2020
Q1 | $93K | Buy |
7,540
+4,702
| +166% | +$58K | ﹤0.01% | 2641 |
|
|
2019
Q4 | $52.5K | Buy |
2,838
+2,511
| +768% | +$46.4K | ﹤0.01% | 2966 |
|
|
2019
Q3 | $4.53K | Buy |
327
+295
| +922% | +$4.09K | ﹤0.01% | 3637 |
|
|
2019
Q2 | $468 | Buy |
+32
| New | +$468 | ﹤0.01% | 3781 |
|